Damien McDonald - LivaNova PLC CEO Director
| LIVN Stock | USD 64.15 1.23 1.95% |
CEO
Mr. Damien McDonald is an Chief Executive Officer, Director of the Company, since January 1, 2017. Mr.. McDonald served as Chief Operating Officer of LivaNova from October 3, 2016 through December 31, 2016. He was an executive officer of LivaNova since October 3, 2016. Prior to joining the Company, Mr.. McDonald held several senior roles in the global life science sector. Most recently, Mr.. McDonald was Group Executive and Corporationrationrate Vice President at Danaher Corporationrationration. From 2013 until 2016, he served as Group President, Professional Consumables at Danaher. During his tenure at Danaher, he was responsible for, among other things, 13 operating plants in Europe and the Americas and over 3, 200 employees globally. From 2011, Mr.. McDonald served as Group President of Kerr Corporationrationration, a subsidiary of Danaher Corporationrationration, where he was responsible for a dental consumables business with operations in the United States, Mexico, Switzerland, Italy and the Czech Republic. In 2010, Mr.. McDonald undertook special projects for Danaher Corporationrationration. From 2007 to 2010, Mr.. McDonald was President, Zimmer Spine at Zimmer Holdings, where he was responsible for divisions in the United States and France. From 1999 to 2007, Mr.. McDonald occupied various roles with Johnson and Johnson. Mr.. McDonald holds bachelors degrees in pharmacy and economics from the University of Queensland in Australia, a masters degree in international economics from the University of Wales, and an MBA from the Institute for Management Development in Lausanne. since 2017.
| Age | 59 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 44 20 3325 0660 |
| Web | https://www.livanova.com |
LivaNova PLC Management Efficiency
The company has return on total asset (ROA) of 0.0231 % which means that it generated a profit of $0.0231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0259) %, meaning that it created substantial loss on money invested by shareholders. LivaNova PLC's management efficiency ratios could be used to measure how well LivaNova PLC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Mark Throdahl | Orthopediatrics Corp | 73 | |
| Joseph Dziedzic | Integer Holdings Corp | 56 | |
| Quentin Blackford | iRhythm Technologies | 45 | |
| Steven Williamson | PulmonxCorp | 51 | |
| Burkhard Prause | Bruker | 57 | |
| Joel Becker | Neuropace | 56 | |
| Bradley Mason | Orthofix Medical | 63 | |
| Massimo Calafiore | Orthofix Medical | N/A | |
| James Corbett | Alphatec Holdings | 56 | |
| Glendon French | PulmonxCorp | 62 | |
| Jeffrey Dunn | Si Bone | 63 | |
| Gary Crosby | Paragon 28 | 61 | |
| Thomas Hook | Integer Holdings Corp | 51 | |
| Albert DaCosta | Paragon 28 | 50 | |
| Terry Rich | Alphatec Holdings | 48 | |
| Kevin King | iRhythm Technologies | 61 | |
Management Performance
| Return On Equity | -0.0259 | ||||
| Return On Asset | 0.0231 |
LivaNova PLC Leadership Team
Elected by the shareholders, the LivaNova PLC's board of directors comprises two types of representatives: LivaNova PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LivaNova. The board's role is to monitor LivaNova PLC's management team and ensure that shareholders' interests are well served. LivaNova PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LivaNova PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pritpal Shinmar, Senior Vice President - Global Market Access | ||
| Daniel Moore, Non-Executive Chairman of the Board | ||
| Stephanie Bolton, President Epilepsy | ||
| Alfred Novak, Independent Director | ||
| Arthur Rosenthal, Independent Director | ||
| Matthew III, Senior IT | ||
| Jacques Gutedel, President - Intercontinental | ||
| Deanna Wilke, Vice Communications | ||
| John Webb, Vice Epilepsy | ||
| Keyna Skeffington, Senior Vice President General Counsel | ||
| Francesco Bianchi, Independent Director | ||
| Demetrio Mauro, Chief Integration Officer | ||
| Sharon OKane, Independent Director | ||
| Vivid Sehgal, CFO | ||
| Hugh Morrison, Independent Director | ||
| Marco Dolci, Pres Unit | ||
| Lindsey Little, Director Relations | ||
| Damien McDonald, CEO Director | ||
| William Kozy, Chairman CEO | ||
| Brian Sheridan, Senior Vice President General Counsel, Company Secretary | ||
| David Wise, Chief Admin. Officer, Sr. VP and Secretary | ||
| AndreMichel Ballester, CEO, Executive Director | ||
| Andrea Saia, Non-Executive Independent Director | ||
| Badri Amurthur, Chief Officer | ||
| Michel Darnaud, President - Cardiac Surgery | ||
| Piero Vecchi, Vice President Controller | ||
| Trui Hebbelinck, Chief Human Resource Officer | ||
| Rohan Hoare, COO | ||
| Edward Andrle, Senior Vice President - Strategy & Business Development | ||
| Michael Hutchinson, Chief VP | ||
| Douglas Manko, Chief Accounting Officer | ||
| Ryan Miller, President Support | ||
| Stefano Gianotti, Independent Director | ||
| Thad Huston, CFO | ||
| Alex Shvartsburg, Chief Officer | ||
| Karen King, Vice President - Investor Relations and Corporate Communications | ||
| Bryan Olin, Senior Neuromodulation | ||
| Vladimir Makatsaria, CEO Director | ||
| Stefano Lullo, President - Cardiac Rhythm Management | ||
| Jonathan Walker, VP Segment |
LivaNova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LivaNova PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0259 | ||||
| Return On Asset | 0.0231 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 3.76 B | ||||
| Shares Outstanding | 54.15 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 99.50 % | ||||
| Number Of Shares Shorted | 3.09 M | ||||
| Price To Earning | 78.67 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards LivaNova PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, LivaNova PLC's short interest history, or implied volatility extrapolated from LivaNova PLC options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LivaNova PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in LivaNova Stock, please use our How to Invest in LivaNova PLC guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for LivaNova Stock analysis
When running LivaNova PLC's price analysis, check to measure LivaNova PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LivaNova PLC is operating at the current time. Most of LivaNova PLC's value examination focuses on studying past and present price action to predict the probability of LivaNova PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LivaNova PLC's price. Additionally, you may evaluate how the addition of LivaNova PLC to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is LivaNova PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LivaNova PLC. If investors know LivaNova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LivaNova PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of LivaNova PLC is measured differently than its book value, which is the value of LivaNova that is recorded on the company's balance sheet. Investors also form their own opinion of LivaNova PLC's value that differs from its market value or its book value, called intrinsic value, which is LivaNova PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LivaNova PLC's market value can be influenced by many factors that don't directly affect LivaNova PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LivaNova PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if LivaNova PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LivaNova PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.